BLCO logo

BAUSCH + LOMB CORP

BLCONYSE
πŸ† #1158 by market capEarnings Nov 4US Equity
$17.14β–² $0.19 (+1.12%)
πŸŒ™ After hours$17.14β–² 0.00%Regular close Β· extended-hours price shown
πŸ””
Track BLCO
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 1.1%
7dβ–² 0.4%
14dβ–² 0.2%
30dβ–Ό 2.0%
ytdβ–² 0.2%
1yβ–² 13.6%
🏦Market Cap
$6.12B
Small Cap
πŸ“ˆRevenue Growth (YoY)
+6.5%
Slowing
πŸ“ŠGross Margin
57.2%
Healthy
πŸ’΅FCF Margin
2.6%
Thin
βš–οΈP/S Ratio
1.2x
Cheap
Otter Score
80
Good

Trading Snapshot

Day Range
$16.89 – $17.21
52-Week Range
$13.77 – $18.92
Volume
$2.61B
Avg Volume
$3.07B
Shares Outstanding
357.2M
Next Earnings
Dec 8, 2026

Fundamentals Snapshot

Annual Revenue
$5.10B
Last Q Revenue
$1.39B
P/E Ratio
-35.8
P/S Ratio
1.2x
EPS (TTM)
$-0.48
Dividend Yield
0.00%
Dilution (1yr)
+0.7%

Why Investors Own BLCO

  • βœ“High-growth profile β€” revenue up +40.5% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 48% gross margin and 29% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

BLCO logo

BAUSCH + LOMB CORP

BLCO
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$5.1Bβ–² +6.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
54.8%β–Ό βˆ’10.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$188Mβ–² +16.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$66Mβ–² +11.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
354.4Mβ–² +0.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$5.0Bβ–Ό βˆ’$356M YoY
StockOtter Β· stockotter.space

About BAUSCH + LOMB CORP

Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Good
80/100

Analyst Price Target

β“˜
Average Target
$21.95
β–² +28.1% Upside
High Target$25.11
Low Target$20.27
Based on 29 analysts

Latest News & Updates

Defense WorldΒ·5d ago

Financial Survey: Merit Medical Systems (NASDAQ:MMSI) vs. Bausch + Lomb (NYSE:BLCO)

Merit Medical Systems (NASDAQ: MMSI - Get Free Report) and Bausch + Lomb (NYSE: BLCO - Get Free Report) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based

Zacks Investment ResearchΒ·15d ago

BLCO Gains European CE Mark for Next-Gen SeeLyra Femtosecond Laser

Bausch + Lomb gains European CE Mark approval for SeeLyra, expanding its surgical portfolio with a compact laser platform for cataract and corneal procedures.

Business WireΒ·18d ago

Bausch + Lomb Announces European CE Mark Approval of SeeLyraβ„’ Femtosecond Laser

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced European CE Mark approval of SeeLy

Business WireΒ·27d ago

Bausch + Lomb Announces New Published Research on enVista Aspireβ„’ Real World Experience

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the publication of new research on

Business WireΒ·28d ago

Most Women Don't Recognize Dry Eye as a Symptom of Perimenopause and Menopause, New Bausch + Lomb Survey Finds

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced findings from a new survey highlig

Zacks Investment ResearchΒ·Aug 25

Bausch + Lomb Advances Two First-in-Class Eye Health Therapies

BLCO advances two eye-health candidates after positive trial results, with combined estimated peak sales exceeding $2 billion.